JP2022517461A5 - - Google Patents

Info

Publication number
JP2022517461A5
JP2022517461A5 JP2021512883A JP2021512883A JP2022517461A5 JP 2022517461 A5 JP2022517461 A5 JP 2022517461A5 JP 2021512883 A JP2021512883 A JP 2021512883A JP 2021512883 A JP2021512883 A JP 2021512883A JP 2022517461 A5 JP2022517461 A5 JP 2022517461A5
Authority
JP
Japan
Prior art keywords
csf
hgm
antibody
pharmaceutical composition
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021512883A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022517461A (ja
Filing date
Publication date
Priority claimed from US16/149,346 external-priority patent/US10870703B2/en
Priority claimed from US16/204,220 external-priority patent/US10899831B2/en
Priority claimed from US16/248,762 external-priority patent/US10927168B2/en
Priority claimed from US16/283,694 external-priority patent/US11130805B2/en
Application filed filed Critical
Priority claimed from PCT/US2019/050494 external-priority patent/WO2020055932A2/en
Publication of JP2022517461A publication Critical patent/JP2022517461A/ja
Publication of JP2022517461A5 publication Critical patent/JP2022517461A5/ja
Pending legal-status Critical Current

Links

JP2021512883A 2018-09-10 2019-09-10 Gm-csfアンタゴニストを使用した免疫療法関連毒性の治療方法 Pending JP2022517461A (ja)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US201862729043P 2018-09-10 2018-09-10
US62/729,043 2018-09-10
US16/149,346 2018-10-02
US16/149,346 US10870703B2 (en) 2017-10-02 2018-10-02 Methods of treating immunotherapy-related toxicity using a GM-CSF antagonist
PCT/US2018/053933 WO2019070680A2 (en) 2017-10-02 2018-10-02 METHODS OF TREATING IMMUNOTHERAPY-RELATED TOXICITY USING GM-CSF ANTAGONIST
USPCT/US2018/053933 2018-10-02
US16/204,220 2018-11-29
US16/204,220 US10899831B2 (en) 2017-10-02 2018-11-29 Method of reducing the level of non-GM-CSF cytokines/chemokines in immunotherapy-related toxicity
US16/248,762 2019-01-15
US16/248,762 US10927168B2 (en) 2017-10-02 2019-01-15 Method of reducing tumor relapse rate in immunotherapy by administration of lenzilumab
US16/283,694 2019-02-22
US16/283,694 US11130805B2 (en) 2017-10-02 2019-02-22 Methods of treating CART-T cell therapy-induced neuroinflammation using a GM-CSF antagonist
PCT/US2019/050494 WO2020055932A2 (en) 2018-09-10 2019-09-10 Methods of treating immunotherapy-related toxicity using a gm-csf antagonist

Publications (2)

Publication Number Publication Date
JP2022517461A JP2022517461A (ja) 2022-03-09
JP2022517461A5 true JP2022517461A5 (cg-RX-API-DMAC7.html) 2022-09-21

Family

ID=69778357

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021512883A Pending JP2022517461A (ja) 2018-09-10 2019-09-10 Gm-csfアンタゴニストを使用した免疫療法関連毒性の治療方法

Country Status (11)

Country Link
EP (1) EP3849572A4 (cg-RX-API-DMAC7.html)
JP (1) JP2022517461A (cg-RX-API-DMAC7.html)
KR (1) KR20210075090A (cg-RX-API-DMAC7.html)
CN (1) CN113164520A (cg-RX-API-DMAC7.html)
AU (1) AU2019340662A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021004489A2 (cg-RX-API-DMAC7.html)
CA (1) CA3111804A1 (cg-RX-API-DMAC7.html)
IL (1) IL281243A (cg-RX-API-DMAC7.html)
MX (1) MX2021002856A (cg-RX-API-DMAC7.html)
SG (1) SG11202102317PA (cg-RX-API-DMAC7.html)
WO (1) WO2020055932A2 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12624086B2 (en) 2018-10-31 2026-05-12 Mayo Foundation For Medical Education And Research Materials and methods for treating cancer
WO2022203908A1 (en) * 2018-10-31 2022-09-29 Humanigen, Inc. Materials and methods for treating cancer
KR20210137085A (ko) 2019-03-05 2021-11-17 엔카르타, 인크. Cd19 유도된 키메라 항원 수용체 및 면역 요법에서 이의 용도
CN114599398A (zh) * 2019-06-03 2022-06-07 基尼克萨制药有限公司 用gm-csf拮抗剂治疗癌症
WO2021204649A1 (en) * 2020-04-06 2021-10-14 Glaxosmithkline Intellectual Property Development Limited Gm-csf antagonists for use in the treatment of severe pulmonary covid-19, cytokine release syndrome and/or acute respiratory distress syndrome
CN113402620B (zh) * 2021-07-30 2021-12-10 中山大学 细胞因子联合嵌合抗原受体的融合蛋白及其应用
CN116887856A (zh) * 2022-01-20 2023-10-13 舒泰神(北京)生物制药股份有限公司 一种特异性地识别粒细胞-巨噬细胞集落刺激因子受体的抗体制剂及其应用
CN114606237B (zh) * 2022-05-11 2025-10-28 上海优替济生生物医药有限公司 Gm-csf抑制剂及其用途
CN119144563B (zh) * 2023-11-24 2025-11-25 成都赛恩吉诺生物科技有限公司 表达gm-csf截短功能区片段的免疫工程细胞及应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8398972B2 (en) * 2006-11-21 2013-03-19 Kalobios Pharmaceuticals, Inc. Methods of treating dementia using a GM-CSF antagonist
KR101824512B1 (ko) * 2008-04-28 2018-02-02 휴머니건, 아이엔씨. 과립구-대식세포 콜로니 자극 인자에 대한 항체
PL4019041T3 (pl) * 2012-07-13 2023-05-08 The Trustees Of The University Of Pennsylvania Kontrola toksyczności wobec aktywności przeciwnowotworowej CAR
US20160024200A1 (en) * 2013-03-14 2016-01-28 John Schrader Human monoclonal antibodies that neutralize bioactivity of granulocyte macrophage colony-stimulating factor and methods and uses thereof
WO2015066262A1 (en) * 2013-11-04 2015-05-07 Trustees Of Dartmouth College Methods for preventing toxicity of adoptive cell therapy
MA46716A (fr) * 2016-11-03 2019-09-11 Juno Therapeutics Inc Polythérapie de thérapie cellulaire et d'inhibiteur de la microglie
CN111757744A (zh) * 2017-10-02 2020-10-09 人源股份有限公司 使用gm-csf拮抗剂治疗免疫疗法相关毒性的方法
US10899831B2 (en) * 2017-10-02 2021-01-26 Humanigen, Inc. Method of reducing the level of non-GM-CSF cytokines/chemokines in immunotherapy-related toxicity
US20210214723A1 (en) * 2018-06-01 2021-07-15 Mayo Foundation For Medical Education And Research Materials and methods for treating cancer

Similar Documents

Publication Publication Date Title
US6969517B2 (en) Recombinant tumor specific antibody and use thereof
US12018084B2 (en) Anti-CXCR2 antibodies and uses thereof
US20250074965A1 (en) Anti-ptk7 immune cell cancer therapy
CN108409860B (zh) 抗人白细胞介素-4受体α单克隆抗体、其制备方法和应用
JP7747367B2 (ja) 抗ヒトtslpモノクローナル抗体及びその使用
JP5987822B2 (ja) 癌胎児性抗原に対する抗体及びその使用
US20220387488A1 (en) Genetically engineered immune cells targeting cd70 for use in treating hematopoietic malignancies
JP2014508511A5 (cg-RX-API-DMAC7.html)
JP2022513412A5 (cg-RX-API-DMAC7.html)
CN113164520A (zh) 使用gm-csf拮抗剂治疗免疫疗法相关毒性的方法
JP2021505183A (ja) ヒトil−5に結合するモノクローナル抗体、その製造方法および用途
Khorasanizadeh et al. Efficacy and safety of benralizumab, a monoclonal antibody against IL-5Rα, in uncontrolled eosinophilic asthma
JP2017527308A (ja) 細胞の細胞質への分子の送達のための構築物
US20220378829A1 (en) Genetically engineered immune cells targeting cd70 for use in treating solid tumors
CN115925940B (zh) 特异性结合cd47的抗体、其重组溶瘤病毒及其用途
JPWO2006046661A1 (ja) インターロイキン−6阻害剤
Mok et al. Non-TNF biologics and their biosimilars in rheumatoid arthritis
JP7450710B2 (ja) 抗pd-l1抗体及びその製薬用途
CN116535509A (zh) 抗CD79b抗体、其制备方法及其应用
TWI825131B (zh) Htlv-1關聯性脊髓病(ham)之治療或預防劑、及ham之治療方法
Matias Drug interactions with therapeutic proteins
AU2017254625B2 (en) Functional plasticity of ILC2, immunity, and COPD
WO2022225821A1 (en) Methods of treating immunotherapy-related toxicity using a gm-csf antagonist
Banić et al. Intestinal Inflammation: Biologics and Small Molecules
CN113929781A (zh) 抗pd-1抗体及其稳定制剂